A Phase I (First-in-Human) Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CAN10, an Anti-IL1RAP Monoclonal Antibody, in Healthy Subjects and in Subjects with Mild to Moderate Plaque Psoriasis

2023-504450-35-00 Protocol CAN10CLIN001 Human pharmacology (Phase I) - First administration to humans Ended

Start 21 Aug 2023 · End 11 Nov 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol CAN10CLIN001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 112
Countries 1
Sites 1

Plaque psoriasis

Key facts

Sponsor
Otsuka Pharmaceutical Development & Commercialization Inc.
Participant type
Patients, Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
21 Aug 2023 → 11 Nov 2025
Decision date (initial)
2023-08-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-504450-35-00
ClinicalTrials.gov
NCT06143371

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Plaque psoriasis

VersionLevelCodeTermSystem organ class
20.0 HLT 10073080 Autoinflammatory diseases 10021428

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Otsuka Pharmaceutical Development & Commercialization Inc.

Sponsor organisation
Otsuka Pharmaceutical Development & Commercialization Inc.
Address
2440 Research Boulevard
City
Rockville
Postcode
20850-3238
Country
United States

Scientific contact point

Organisation
Otsuka Pharmaceutical Development & Commercialization Inc.
Contact name
Olga Sergeyeva

Public contact point

Organisation
Otsuka Pharmaceutical Development & Commercialization Inc.
Contact name
Suzanne Watkin

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 112 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
CRS Clinical Research Services Management GmbH
Clinic, Siemensdamm 65, Siemensstadt, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2023-08-21 2025-11-10 2023-08-21 2025-09-18

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-04-20 Germany Acceptable
2023-08-07
2023-08-10
2 SUBSTANTIAL MODIFICATION SM-1 2024-01-12 Germany Acceptable
2024-02-19
2024-02-26
3 SUBSTANTIAL MODIFICATION SM-2 2024-10-09 Germany Acceptable
2024-11-18
2024-11-20
4 SUBSTANTIAL MODIFICATION SM-3 2025-09-26 Germany Acceptable
2025-10-06
2025-10-08
5 SUBSTANTIAL MODIFICATION SM-4 2025-11-27 Germany Acceptable
2025-12-18
2025-12-18